Several clinical trials are currently evaluating PERK inhibitors in various types of cancer. These trials aim to determine the safety, efficacy, and optimal dosing of PERK-targeting drugs. Early-phase trials have shown promising results, but more research is needed to fully understand the therapeutic potential and limitations of PERK inhibition in cancer treatment.
